Thelansis

  Fibrolamellar carcinoma, or FLC, is a rare cancer of the liver that usually grows in teens and adults under 40 years old. This type of cancer is different from other types of liver cancer because it happens in people who have healthy livers. Etiology- The exact underlying cause of fibrolamellar carcinoma (FLC) is poorly understood. Recent research suggests that a deletion on chromosome 19, which leads to the abnormal combination of two genes, the DNAJB1 and the PRKACA genes may play a key role in the FLC.   Epidemiology- It affects both men and women and affects approximately 1 in 5,000,000 people in the general population.   The competitive landscape of Fibrolamellar Carcinoma includes country-specific approved as well as pipeline therapies. Any asset/product-specific designation or review and Accelerated Approval are being tracked and supplemented with analyst commentary. KOLs insights of Fibrolamellar Carcinoma across 8 MM market from the centre of E...